27547432|t|Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis
27547432|a|The presence of myocardial fibrosis by cardiac MRI has prognostic value in cardiac sarcoidosis, and localisation may be equally relevant to clinical outcomes. We aimed to analyse cardiac damage and function in detail and explore the relationship with clinical outcomes in patients with cardiac sarcoidosis using cardiac MRI. We included 81 consecutive patients with cardiac sarcoidosis undergoing cardiac MR. Left ventricular mass and fibrosis mass were calculated, and localisation was analysed using a 17-segment model. Participants underwent follow-up through 2015, and the development of major adverse cardiac events including ventricular tachyarrhythmias was recorded. Increased left ventricular fibrosis mass was associated with increased prevalence of ventricular tachyarrhythmias (p<0.001). When localisation was defined as the sum of late gadolinium enhancement in the left ventricular basal anterior and basal anteroseptal area s, or the right ventricular area, it was associated with ventricular tachyarrhythmias (p<0.001). Kaplan-Meier analysis during a median follow-up of 22.1 months showed that both the mass and localisation groupings for fibrosis were significantly associated with major adverse cardiac events or ventricular tachyarrhythmias and that when combined, the risk stratification was better than for each variable alone (p<0.001, respectively). By Cox-proportional hazard risk analysis, the localisation grouping was an independent predictor for the both. In patients with cardiac sarcoidosis, both fibrosis mass and its localisation to the basal anterior / anteroseptal left ventricle, or right ventricle was associated with the development of major adverse cardiac events or ventricular tachyarrhythmias. Cardiac MR with late gadolinium enhancement may be useful for improving risk stratification in patients with cardiac sarcoidosis.
27547432	5	19	stratification	T062	UMLS:C1514983
27547432	30	52	adverse cardiac events	T033	UMLS:C1556247
27547432	57	85	ventricular tachyarrhythmias	T038	UMLS:C0042514
27547432	89	100	cardiac MRI	T058	UMLS:C0412692
27547432	118	137	cardiac sarcoidosis	T038	UMLS:C0392077
27547432	154	173	myocardial fibrosis	T038	UMLS:C0151654
27547432	177	188	cardiac MRI	T058	UMLS:C0412692
27547432	193	209	prognostic value	T201	UMLS:C1514474
27547432	213	232	cardiac sarcoidosis	T038	UMLS:C0392077
27547432	278	295	clinical outcomes	T033	UMLS:C0243095
27547432	336	344	function	T038	UMLS:C0232164
27547432	389	406	clinical outcomes	T033	UMLS:C0243095
27547432	424	443	cardiac sarcoidosis	T038	UMLS:C0392077
27547432	450	461	cardiac MRI	T058	UMLS:C0412692
27547432	504	523	cardiac sarcoidosis	T038	UMLS:C0392077
27547432	535	545	cardiac MR	T058	UMLS:C0412692
27547432	547	568	Left ventricular mass	T033	UMLS:C0455825
27547432	573	581	fibrosis	T038	UMLS:C0016059
27547432	582	586	mass	T033	UMLS:C0577559
27547432	660	672	Participants	T098	UMLS:C0679646
27547432	683	692	follow-up	T058	UMLS:C1522577
27547432	736	758	adverse cardiac events	T033	UMLS:C1556247
27547432	769	797	ventricular tachyarrhythmias	T038	UMLS:C0042514
27547432	822	838	left ventricular	T017	UMLS:C0225897
27547432	839	847	fibrosis	T038	UMLS:C0016059
27547432	848	852	mass	T033	UMLS:C0577559
27547432	897	925	ventricular tachyarrhythmias	T038	UMLS:C0042514
27547432	981	1008	late gadolinium enhancement	T103	UMLS:C3249258
27547432	1016	1047	left ventricular basal anterior	T017	UMLS:C4288836
27547432	1052	1075	basal anteroseptal area	T017	UMLS:C4288834
27547432	1086	1108	right ventricular area	T017	UMLS:C0456871
27547432	1133	1161	ventricular tachyarrhythmias	T038	UMLS:C0042514
27547432	1211	1220	follow-up	T058	UMLS:C1522577
27547432	1257	1261	mass	T033	UMLS:C0577559
27547432	1293	1301	fibrosis	T038	UMLS:C0016059
27547432	1343	1365	adverse cardiac events	T033	UMLS:C1556247
27547432	1369	1397	ventricular tachyarrhythmias	T038	UMLS:C0042514
27547432	1431	1445	stratification	T062	UMLS:C1514983
27547432	1514	1551	Cox-proportional hazard risk analysis	T170	UMLS:C0010235
27547432	1586	1597	independent	T033	UMLS:C1299583
27547432	1639	1658	cardiac sarcoidosis	T038	UMLS:C0392077
27547432	1665	1673	fibrosis	T038	UMLS:C0016059
27547432	1674	1678	mass	T033	UMLS:C0577559
27547432	1707	1721	basal anterior	T017	UMLS:C0555926
27547432	1724	1751	anteroseptal left ventricle	T017	UMLS:C1300766
27547432	1756	1771	right ventricle	T017	UMLS:C0456871
27547432	1817	1839	adverse cardiac events	T033	UMLS:C1556247
27547432	1843	1871	ventricular tachyarrhythmias	T038	UMLS:C0042514
27547432	1873	1883	Cardiac MR	T058	UMLS:C0412692
27547432	1889	1916	late gadolinium enhancement	T103	UMLS:C3249258
27547432	1950	1964	stratification	T062	UMLS:C1514983
27547432	1982	2001	cardiac sarcoidosis	T038	UMLS:C0392077